Vark Industries, Inc. Internal Medicine - Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 4216 Little Rd, New Port Rickey, FL 34655 Phone: 727-807-5618 Fax: 727-807-5733 |
News Archive
Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.
A new study suggests that while healthy preterm children have more medical sleep problems than full-term children, they are more likely to fall asleep independently.
Suppose someone showed you a novel gadget and told you, "Here's how it works," while demonstrating a single function, such as pushing a button. What would you do when they handed it to you?
Ms Hewitt has promised a "much stronger" legal framework in the National Health Service (NHS) to help hospitals reduce the rate of antibiotic-resistant MRSA and other hospital acquired infections.
› Verified 4 days ago